Emma Sceats

Chief Executive Officer

CN Bio Innovations

CN Bio’s aim is to transform drug discovery and development by replacing animal testing with experiments on sophisticated mimics of human organs

Emma-Sceats

Under Emma’s leadership CN Bio has completed deals with 25 pharma, raised £5 million in equity investment and secured £2 million research funding. CN Bio are currently working with the Massachusetts Institute of Technology on a $26 million US Department of Defense contract to build a human body-on-a-chip: a tablet sized device containing ten miniature interacting human organs.

Emma is a chemist by training and was a Presidential scholar at MIT and a graduate scholar at Oxford.